权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Phosphodiesterase 10A, a novel target for lung cancer chemoprevention

磷酸二酯酶10A，肺癌化学预防的新靶点

基本信息

批准号：
10456469
负责人：
Gary A Piazza
金额：
$ 26.74万
依托单位：
AUBURN UNIVERSITY AT AUBURN
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-23 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10456469
关键词：
Phosphodiesterase 10A novel target lung

项目摘要

Abstract Preclinical, clinical and epidemiological studies provide compelling evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) have antineoplastic activity and significantly reduce the incidence and risk of death from multiple cancer types, including lung cancer. Unfortunately, the long-term use of NSAIDs for chemoprevention and their potential application for therapy are not recommended because of the risk of potentially fatal side-effects resulting from cyclooxygenase (COX) inhibition and the suppression of physiologically important prostaglandins. However, numerous investigators have concluded that the pharmacological basis for their antineoplastic activity may not require COX inhibition, which suggests the feasibility of developing safer and more efficacious non-COX inhibitory derivatives for cancer by targeting the underlying mechanism. We have extensively studied the mechanism by which the NSAID, sulindac inhibits tumor cell growth and have reported that this activity results from cyclic guanosine monophosphate phosphodiesterase (cGMP PDE) inhibition and the activation of cGMP/protein kinase G signaling to suppress oncogenic β-catenin/Tcf-transcriptional activity and the synthesis of key proteins, such as cyclin D1 and survivin that drive tumor cell proliferation and survival. Here we show that the cGMP degrading PDE isozyme, PDE10A is a critically important target of sulindac that is elevated in lung tumors and essential for lung tumor cell growth. Guided by molecular modeling using the crystal structure of PDE10, we synthesized a novel series of sulindac derivatives that potently and selectively inhibit lung tumor cell growth without inhibiting COX-1 or COX-2. These compounds have attractive drug-like properties whereby high lung concentrations relative to plasma and other tissues can be safely achieved by oral administration. A lead compound, MCI-048 was identified that displays strong antitumor activity in an orthotopic mouse model of lung cancer. Further analog development to identify a preclinical drug development candidate and studies to better define the role of PDE10 in lung cancer are therefore urgently needed. The following aims are proposed: 1) synthesize a novel series of sulindac derivatives to improve potency and selectivity, 2) evaluate PDE10 and lung tumor cell growth inhibitory activity of sulindac derivatives, 3) evaluate antitumor activity of sulindac derivatives in mouse models of lung cancer, and 4) further define the role of PDE10 in lung cancer. The focus of this project on the development of novel anticancer drugs and target validation for chemoprevention or therapy have the potential to impact individuals at risk of developing lung cancer as well as patients with advanced stage malignant disease.

摘要

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The RAS-Effector Interaction as a Drug Target.

RAS-效应器相互作用作为药物靶点。

DOI：
10.1158/0008-5472.can-16-0938
发表时间：
2017-01-15
期刊：
Cancer research
影响因子：
11.2
作者：
Keeton AB;Salter EA;Piazza GA
通讯作者：
Piazza GA

Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10.

DOI：
10.18632/oncotarget.4741
发表时间：
2015-09-29
期刊：
Oncotarget
影响因子：
0
作者：
Li N;Chen X;Zhu B;Ramírez-Alcántara V;Canzoneri JC;Lee K;Sigler S;Gary B;Li Y;Zhang W;Moyer MP;Salter EA;Wierzbicki A;Keeton AB;Piazza GA
通讯作者：
Piazza GA

Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.

DOI：
10.1016/j.bioorg.2020.104322
发表时间：
2020-11
期刊：
Bioorganic chemistry
影响因子：
5.1
作者：
Abdel-Halim M;Tinsley H;Keeton AB;Weam M;Atta NH;Hammam MA;Hefnawy A;Hartmann RW;Engel M;Piazza GA;Abadi AH
通讯作者：
Abadi AH

Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion.